Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer after docetaxel
ACTRN12617001590358Phase 2Completed
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Feb 2018
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan and cabazitaxel in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC), sponsored by ANZUP Cancer Trials Group. Primary endpoint: PSA response rate. Started Feb 2018; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetancabazitaxel
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ACTRN12617001590358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001590358.